Implantable Optical Sensor for Interstitial Fluid Monitoring
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for monitoring end-stage renal disease (ESRD) are inadequate, particularly for patients undergoing dialysis, as they are invasive, expensive, and lack accuracy in measuring renal function, leading to poor disease management and reduced patient compliance.
Innovation Solution
An implantable analyte sensor system that monitors interstitial fluid for creatinine, BUN, glucose, and potassium levels, using a reagent system that changes color or emits light to indicate analyte concentrations, readable by a personal electronic device, allowing for more accurate and convenient monitoring of renal function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional blood testing methods are used to monitor renal function, then measurement accuracy is maintained, but patient compliance deteriorates due to pain and inconvenience
Solution Approach 1:
The patent replaces the mechanical invasive blood sampling system with an optical sensing system. The implantable sensor uses optical detection methods to measure analyte concentrations in interstitial fluid, eliminating the need for repeated needle punctures and blood draws, thereby maintaining measurement reliability while dramatically improving patient comfort and compliance
Solution Approach 2:
The patent introduces interstitial fluid as an intermediary medium between the blood and the external testing system. By measuring analyte concentrations in interstitial fluid through an implantable sensor, the system provides continuous monitoring without requiring direct blood sampling, thus maintaining accuracy while improving ease of operation
2Ease of operation
If implantable sensors are used to improve patient compliance, then testing convenience is improved, but device complexity and cost increase
Solution Approach 1:
The patent extracts the sensing function from a complex powered system and creates a passive implantable sensor that relies on the body's natural interstitial fluid for operation. By removing the need for power sources, data transmission components, and complex electronics within the implant, the device achieves simplicity while maintaining ease of operation
Solution Approach 2:
The patent employs a disposable implantable sensor that is inexpensive to manufacture and replace. The sensor is designed for single-use or limited-duration implantation, eliminating the need for expensive, sophisticated, reusable implantable systems with power sources and complex electronics, thus reducing device complexity and cost
3Reliability
If dialysis treatments are administered to manage ESRD, then patient survival is improved, but measurement accuracy deteriorates due to low blood analyte concentrations
Solution Approach 1:
The patent uses interstitial fluid as an intermediary that maintains stable analyte concentrations even during dialysis treatments. By measuring analytes in interstitial fluid rather than blood, the system provides continuous accurate monitoring that reflects the body's toxin state before, during, and after dialysis, thereby improving measurement precision while patient survival benefits from optimized dialysis timing
Solution Approach 2:
The patent implements continuous monitoring with feedback capability that tracks analyte concentrations in real-time. This allows for optimization of dialysis treatment timing and duration based on actual body toxin levels, improving both measurement precision and patient survival outcomes through data-driven treatment adjustments
4Reliability
If frequent monitoring is implemented to improve disease management, then patient outcomes are improved, but loss of time and resources increases
Solution Approach 1:
The patent enables continuous monitoring of analyte concentrations through an implantable sensor that operates continuously without requiring patient intervention. This provides uninterrupted data on renal function and toxin levels, improving disease management quality while eliminating the time loss associated with repeated hospital visits and manual blood draws
Solution Approach 2:
The patent creates a self-monitoring system where the implantable sensor automatically measures and tracks analyte concentrations without requiring patient action. The sensor performs self-service monitoring, continuously providing data that improves disease management quality while eliminating the time and resource burden on patients and healthcare providers
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This system enables better management of ESRD by providing real-time data for dialysis treatment optimization, improving patient outcomes and extending the life expectancy of ESRD patients by allowing for tailored treatment and early detection of renal disease progression.
Implementation Method 1
using a reagent system that changes color or emits light to indicate analyte concentrations
Implementation Method 2
using a reagent system that changes color or emits light to indicate analyte concentrations
Data Source
AI summary
An end stage renal disease (ESRD) monitoring system may include an implantable sensor and a reader device with an optical sensor. The implantable sensor may be configured to detect a group of analytes relevant to ESRD, such as glucose, creatinine, urea, and potassium. The implantable sensor may be implanted into the dermis of an animal, and may exhibit color changes in response to the presence of the target analytes or reaction product(s) thereof. The reader device may be configured to capture an image of the implanted sensor and to determine the concentration of the target analytes based at least in part on the image. The reader device may be a personal electronic device such as a cell phone, PDA, or personal computer.